Anavex Life Sciences (Nasdaq: AVXL) will present one oral late-breaking communication and two poster presentations on oral blarcamesine at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, December 1–4, 2025.
Presentations include an oral LB11 on December 2 reporting that the Phase IIb/III trial "confirms identified precision medicine patient population" with reported broad clinical and quality-of-life improvements, and two posters (P076, P084) comparing outcomes to prodromal cognitive aging and discussing patient/family convenience. Company commentary notes Phase IIb/III signals of slowed cognitive decline and an adequate safety profile with no ARIA reported.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.